Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Optimizing dosage to prevent emergence of resistance - lessons from in vitro models.

Singh R, Tam VH.

Curr Opin Pharmacol. 2011 Oct;11(5):453-6. doi: 10.1016/j.coph.2011.07.009. Epub 2011 Aug 23. Review.

PMID:
21868287
2.

A scoring model of factors associated with Candida glabrata candidemia among critically ill patients.

Tapia GG, Razonable RR, Eckel-Passow JE, Lahr BD, Afessa B, Keegan MT, Catania J, Baddour LM.

Mycoses. 2012 May;55(3):228-36. doi: 10.1111/j.1439-0507.2011.02069.x. Epub 2011 Jul 21.

PMID:
21777296
3.

Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes.

Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, Garey KW.

J Antimicrob Chemother. 2011 Sep;66(9):2146-51. doi: 10.1093/jac/dkr244. Epub 2011 Jun 23.

PMID:
21700622
4.

Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.

Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F; French Mycosis Study Group..

Antimicrob Agents Chemother. 2011 Feb;55(2):532-8. doi: 10.1128/AAC.01128-10. Epub 2010 Nov 15.

5.

Risk factors for fluconazole-resistant candidemia.

Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, Ruiz Pérez de Pipaón M, Hernández-Caballero C, Aznar-Martín J, Cisneros JM, Ortiz-Leyba C.

Antimicrob Agents Chemother. 2010 Aug;54(8):3149-54. doi: 10.1128/AAC.00479-10. Epub 2010 May 24.

6.

Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?

Oxman DA, Chow JK, Frendl G, Hadley S, Hershkovitz S, Ireland P, McDermott LA, Tsai K, Marty FM, Kontoyiannis DP, Golan Y.

J Antimicrob Chemother. 2010 Jul;65(7):1460-5. doi: 10.1093/jac/dkq136. Epub 2010 Apr 29.

PMID:
20430790
7.

Predictors of candidaemia caused by non-albicans Candida species: results of a population-based surveillance in Barcelona, Spain.

Rodríguez D, Almirante B, Cuenca-Estrella M, Rodríguez-Tudela JL, Mensa J, Ayats J, Sanchez F, Pahissa A; Barcelona Candidemia Project Study Group..

Clin Microbiol Infect. 2010 Nov;16(11):1676-82. doi: 10.1111/j.1469-0691.2010.03208.x.

8.

Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death.

Slavin MA, Sorrell TC, Marriott D, Thursky KA, Nguyen Q, Ellis DH, Morrissey CO, Chen SC; Australian Candidemia Study, Australasian Society for Infectious Diseases..

J Antimicrob Chemother. 2010 May;65(5):1042-51. doi: 10.1093/jac/dkq053. Epub 2010 Mar 4.

PMID:
20202987
10.

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD; Infectious Diseases Society of America..

Clin Infect Dis. 2009 Mar 1;48(5):503-35. doi: 10.1086/596757.

PMID:
19191635
11.

Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp.

Playford EG, Marriott D, Nguyen Q, Chen S, Ellis D, Slavin M, Sorrell TC.

Crit Care Med. 2008 Jul;36(7):2034-9. doi: 10.1097/CCM.0b013e3181760f42.

PMID:
18552700
12.

Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit.

Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D, Chawla V, Young J, Hadley S.

Clin Infect Dis. 2008 Apr 15;46(8):1206-13. doi: 10.1086/529435.

PMID:
18444857
13.

Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines.

Garey KW, Pai MP, Suda KJ, Turpin RS, Rege MD, Mingo DE, Bearden DT.

Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):919-27.

PMID:
17286303
14.
15.
16.
17.

Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.

Andes D, Forrest A, Lepak A, Nett J, Marchillo K, Lincoln L.

Antimicrob Agents Chemother. 2006 Jul;50(7):2374-83.

18.
19.

Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study.

Lin MY, Carmeli Y, Zumsteg J, Flores EL, Tolentino J, Sreeramoju P, Weber SG.

Antimicrob Agents Chemother. 2005 Nov;49(11):4555-60.

20.

Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.

Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH.

Antimicrob Agents Chemother. 2005 Aug;49(8):3171-7.

Supplemental Content

Support Center